Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
The aim of the Marie Sklodowska-Curie Doctoral Network “eRaDicate” is to develop new therapies against cancer stem cell-driven relapse and metastasis. The 11 doctoral candidates (DCs) of eRaDicate will be trained not only to perform original and independent research on an internationally competitive level, but will also be endowed with a creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
eRaDicate is hiring!
We are currently recruiting a Doctoral Candidate (DC) for a PhD position at the University of Wrocław in the field of leukaemia research.
Application deadline: 14.06.2026.
All information for the application can be found on the Euraxess page.
The application documents can be downloaded here:
Application Form
Referee Form
Please note that only complete applications will be considered. This includes the application form, research exposé. academic CV, graduation certificates, proof of English language proficiency, valid ID & proof of eligibility, and two letters of refernce & referee form (to be submitted by the referees). See the Euraxess job offer for all the details.
News
Bringing Biotechnology to Life: Hands-On Workshop for Students
Mathilde Rey, the DC from University of Wroclaw, Department of Biotechnology, together with her colleague Subhradeep Haldar, organised a hands-on scientific workshop…
eRaDicate’s participation in the Long Night of Research
In April 2026, several members of the eRaDicate team took part in the Long Night of Research at the Medical University of Vienna. Among the participants…
Agnes Graf’s secondment to Physiolution
In March 2026, I had the opportunity to complete my second secondment at Physiolution in Wrocław, Poland. Physiolution specializes in bio-predictive solubility and dissolution…
Consortium
The eRaDicate consortium consists of eight academic and one industrial and beneficiaries, as well as twelve associated partners to provide training and secondments.
Beneficiaries
Associated Partners




